Unequal Distribution of CAR T-Cell Therapy in Childhood Cancer

Strategic Insights -

A new study has highlighted a significant issue in pediatric oncology research worldwide. Investigators from Universidad de Manizales in Colombia have found that the global distribution of chimeric antigen receptor (CAR) T-cell therapy for childhood cancer is unequal, with limited access in regions bearing a high burden of disease. The study, published in Frontiers in Pediatrics, analyzed global health metrics, child cancer indicators, and data from the Global Observatory on Health Research and Development. The research reveals that clinical trials for CAR T-cell therapy are concentrated in high-income countries, such as China and the United States, rather than in countries with the greatest health needs.

Key Takeaways:

  • The global distribution of CAR T-cell therapy for childhood cancer is unequal, with limited access in regions bearing a high burden of disease.
  • A total of 414 CAR T-cell therapy clinical trial participations across 30 countries were identified, with a heavy concentration in China (n = 161) and the United States (n = 84).
  • High-income countries represented 73.3% of those participating in clinical trials.
  • Multiple linear regression identified only one significant predictor for clinical trials participation: youth mortality.
  • The study reveals a structural misalignment between childhood cancer disease burden and research activity in advanced therapies.
  • Clinical trials are concentrated in countries with stronger scientific infrastructure rather than those with the greatest health needs.
  • The findings reinforce cancer scientific inequities in the production and distribution of biomedical knowledge.

Statistics:

  • 414 CAR T-cell therapy clinical trial participations across 30 countries.
  • 73.3% of clinical trials participations were from high-income countries.
  • 161 clinical trial participations were from China.
  • 84 clinical trial participations were from the United States.
  • 73.3% of high-income countries were represented in clinical trials.

Sources:

NewsRx. Universidad de Manizales Researchers Focus on Cancer (Bridging the gap: cancer scientific equity, global child health, and distribution of CAR T-cell therapy clinical trials in childhood cancer). Cancer Weekly. July 22, 2025; p 507.

Bridging the gap: cancer scientific equity, global child health, and distribution of CAR T-cell therapy clinical trials in childhood cancer. Frontiers in Pediatrics, 2025,13. (Frontiers in Pediatrics - http://journal.frontiersin.org/journal/pediatrics)

Frontiers Media S.A. (2025). Bridging the gap: cancer scientific equity, global child health, and distribution of CAR T-cell therapy clinical trials in childhood cancer. doi: 10.3389/fped.2025.1611187